Jill Broadfoot

Back to Jobs

Jill Broadfoot has served on our board of directors since August 2021. Since July 2018, Ms. Broadfoot has served as Chief Financial Officer (CFO) of aTyr Pharma. Prior to joining aTyr, she served as CFO of Emerald Health Pharmaceuticals and Emerald Health Bioceuticals where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceuticals entities as well as the establishment of operations, corporate governance, finance and accounting, and investor relations functions. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as CFO of Vical, held various positions at DJO Global including Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot currently serves as a member of the board of directors of AcelRx Pharmaceuticals. She holds a B.S. in business administration and accounting from San Diego State University and is a Certified Public Accountant.

Apply Now